New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
09:06 EDTNUVA, ABCO, BSX, CMN, DGX, ELGX, FLDM, STJ, THORPiper Jaffray's technical analyst holds an analyst/industry conference call
Technical Analyst Johnson provides a technical review of the firm's Medical Technology covered universe ahead of 4Q results on an Analyst/Industry conference call to be held on January 10 at 10 am.
News For ABCO;BSX;CMN;DGX;ELGX;FLDM;STJ;THOR;NUVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 29, 2014
08:32 EDTCMNCantel Medical reports Q4 EPS 26c, consensus 26c
Reports Q4 revenue $131.38M, one estimate $125.14M
07:24 EDTELGXStephens to hold an investor trip
Subscribe for More Information
07:09 EDTELGXEndologix reports preliminary Q3 revenue approximately $37M, consensus $37.68M
Subscribe for More Information
07:07 EDTELGXEndologix lowers FY14 adjusted EPS view to (43c)-(37c) from (33c)-(27c)
Subscribe for More Information
06:56 EDTELGXEndologix completes enrollment in EVAS FORWARD – Global Registry
Subscribe for More Information
06:51 EDTELGXEndologix to initiate prospective randomized EVAR clinical study
Endologix announced that it will conduct the first ever prospective randomized clinical study to compare outcomes in endovascular repair of abdominal aortic aneurysms. The LEOPARD Study has been designed to provide an accurate and unbiased assessment of commercially available EVAR devices with a planned enrollment of 600 patients. LEOPARD will include up to 60 active EVAR centers throughout the United States. The primary endpoint of the study is treatment success at one year based upon: procedural success; and rates of freedom from aneurysm rupture; conversion to open surgical repair; endoleaks; clinically significant device migration; aneurysm enlargement and secondary endovascular procedures. Results from the study will be independently adjudicated by a third-party. The follow-up period will be five years.
September 24, 2014
16:41 EDTBSXCourt says Boston Scientific breached license agreement
Boston Scientific disclosed in a regulatory filing that on September 24, following a jury verdict against Boston Scientific Corporation, the Montgomery County Circuit Court in Maryland entered a judgment that the company breached its license agreement with Mirowski Family Ventures and awarded damages of $308M. The company believes the facts and the law do not support the jury’s findings or the amount of the damages. The company plans to seek to overturn the judgment in post-trial motions with the Circuit Court and, if necessary, through the appeals process.
September 23, 2014
16:09 EDTBSXBoston Scientific enrolls first patients in U.S. trial of Lotus Valve System
Boston Scientific has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus Valve System in patients with severe aortic stenosis and who are considered to be at either high or extreme risk for surgical valve replacement. The Lotus Valve System is the first transcatheter aortic valve replacement device that is both fully repositionable and retrievable prior to release. The primary endpoints of the study are Safety; composite of all-cause mortality, stroke, life-threatening and major bleeding events, stage two or three acute kidney injury or major vascular complications at 30 days. Efficacy; composite of all-cause mortality, disabling stroke or moderate or greater paravalvular aortic regurgitation at one year following procedure.
09:45 EDTSTJLeerink medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Antalffy discusses the ultimate market opportunity for leadless pacers and compares Medtronic vs St. Jude Medical on an Analyst/Industry conference call to be held on September 24 at 2 pm.
September 22, 2014
08:32 EDTSTJSt. Jude receives CE Mark approval of Tendril STS, IsoFlex Optim labeling
Subscribe for More Information
07:35 EDTTHORThoratec sees Q3 revenue $102M-$107M, consensus $109.54M
Subscribe for More Information
07:34 EDTTHORThoratec appoints Keith Grossman President and CEO
Subscribe for More Information
06:51 EDTSTJSt. Jude Medical recent weakness a buying opportunity, says Barclays
Barclays said St. Jude Medical weakness is a buying opportunity. The analyst said CardioMEMS is underappreciated by the Street and valuation compelling given sequential revenue growth. Shares are Overweight rated.
September 18, 2014
14:49 EDTABCOThe Advisory Board management to meet with Craig-Hallum
Meeting to be held in Milwaukee on September 24 hosted by Craig-Hallum.
September 17, 2014
11:41 EDTTHORLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
07:47 EDTFLDMFluidigm shares recommended at Maxim
Subscribe for More Information
07:43 EDTBSXBofA/Merrill to hold a conference
Subscribe for More Information
05:09 EDTBSXBoston Scientific receives CE Mark for Vercise DBS system
Subscribe for More Information
September 16, 2014
07:58 EDTBSXBoston Scientific product still likely to get nod despite data, says Wells Fargo
Although new data presented at TCT showed that the confirmatory PREVAIL study of Boston Scientific's Watchman device missed both co-primary efficacy endpoints, Wells Fargo still thinks there is a 60%-70% chance of an FDA panel recommending approval of the device on October 8. Wells keeps an Outperform rating on the stock.
05:15 EDTSTJData shows PA pressure monitoring did not adversely affect kidney function
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use